Imunoriks

Imunoriks is a medicine that stimulates the immune reactions of the body.

Indications of the imoonorix

It is used to stimulate cellular immune reactions, when diagnosing immunosuppression against a background of infectious lesions affecting the urinary system or respiratory organs.

Release form

Release in the form of an oral solution in glass bottles with a volume of 7 ml (per 1 dosage). Inside the packet there are 10 bottles of solution.

Pharmacodynamics

Pidotimod affects the body by stimulating the processes of the cellular immune response, as well as their regulation.

In the case of a lack of T-lymphocytes, which are coordinators of a specific immune response under physiological conditions, the pidotimod substance, partially replacing or strengthening the activity of the thymus, promotes the formation of T-lymphocytes, and in addition, the achievement by these elements of a full-fledged immune response to the required responses.

Along with this, the drug stimulates the activity of macrophages responsible for the absorption of the antigen, and in addition for the presence of this element on the surface of the membrane - for antigens responsible for histocompatibility. The protective functions of the organism in relation to infectious agents depend on the degree of effectiveness of specific cellular, as well as immune and humoral reactions.

Drugally significant properties of the substance pidotimoda due to the presence of immunostimulating activity in relation to the natural immune function, as well as the effect on antibody production, cellular immune response and cytokine production.

Pidotimod increases the amount of superoxide anions produced by the body, and in addition TNFα and NO (bactericidal effect). Also, the element stimulates the activity of chemotaxis and, at the same time, the process of phagocytosis. The medicine increases the cytotoxic activity of natural killers.

Pidotimod increases the functional effect of T- and also B-lymphocytes, increases the effectiveness of the call of the antibody reaction, and at the same time interferes with the process of apoptosis, which is caused by dexamethasone, as well as 12-B-tetradecanoylpherbol-13-acetate and ionophor of the A-23l87 group (calcium type).

The drug enhances the nonspecific protective function of the body - increasing the production of immunoglobulin category A. In addition, significantly increases the number of produced cytokines (such as IL-2), as well as γ-interferons.

Pharmacokinetics

Pharmacokinetic tests with volunteers demonstrated that after absorption of the solution, high absorption rates are observed. The bioavailability level reaches 45%, the half-life is 4 hours. Excretion of drugs is carried out together with urine (unchanged substance) - 95% of the accepted dosage.

The degree and speed of the ongoing absorption of the drug is significantly reduced when used in combination with food. After oral ingestion with food, the bioavailability values drop by 50%, and peak serum levels are required to be 2 hours longer than in the case of fasting.

The active ingredient is excreted completely with urine. If the patient has renal failure, the half-life is prolonged. But even in the case of a severe form of this disease (the creatinine value in the plasma is 5 mg / dl), the half-life of the substance lasted no more than 8-9 hours.

Due to the fact that patients use the medication with interruptions in 12 or 24 hours, there is no risk of accumulation of drugs with kidney failure.

Dosing and administration

The size of adult dosages: take the contents of 2 bottles (calculated per dose) - 800 mg 2 times a day for 15 days.

The sizes of children's dosages (over 3 years old): take the contents of the 1st vial (calculated for a single dose) - 400 mg 2 times a day for a period of 15 days.

You can adjust the size of doses and the duration of the course of use, given the severity of the signs of the disease, as well as its severity. But the course in any case can last no more than 3 months.

To eliminate infectious lesions of recurrent type in people with a risk of developing immunodeficiency (or with its presence in the anamnesis) it is required to use: for adults, 800 mg, and for children, 400 mg of solution in the period of 2 months (as a supporting treatment).

[1]

Use of the imoonorix during pregnancy

Information on the use of Imunorix in pregnant women is not enough to draw conclusions about its safety. Although during animal tests there was no adverse effect of drugs on reproductive activity, it is not recommended to use it during pregnancy.

Information on the passage of the pidotimod or its decay products into the mother's milk is not available, but it is recommended to abandon breastfeeding during the period of drug use - in order to avoid the impact of the pidotimod on the baby.

Contraindications

The main contraindications: hypersensitivity to the elements of the medicine, as well as children's age less than 3 years.

Side effects of the imoonorix

Reception of a solution sometimes causes the appearance of such side effects:

• Immune disorders: single development of rheumatic purpura and uveitis was noted;
• lesions of the digestive system: there was a single nausea, abdominal pain or diarrhea;
• lesions of the skin and subcutaneous layers: single symptoms of allergic dermatitis (among them rashes, hives, as well as itching and swelling of the lips).

Interactions with other drugs

Pidotimod does not undergo protein synthesis inside the plasma. The substance does not pass through metabolic processes, and therefore no pharmacokinetic interactions should be expected.

The drug is able to enter into interactions with drugs that stimulate or slow down lymphocyte activity, or have an effect on immune functions.

Animal tests have shown that no adverse reactions were observed when using the drug in combination with common drugs. Among the drugs used in the tests: phenobarbital (a drug for general anesthesia), tolbutamide (a drug that lowers the sugar), chlorothiazide (a diuretic drug), warfarin (anticoagulant), captopril with nifedipine and atenolol (antihypertensive drugs), acetylsalicylates (analgesic) , indomethacin (NSAIDs) and paracetamol (an antipyretic drug).

[2], [3]

Storage conditions

The solution should be stored in a place that is closed from moisture and sunlight, and out of the reach of small children. Optimum temperature values are a maximum of 30 ° C.

[4]

Special instructions

Reviews

Imunorix is considered to be a fairly effective remedy - medical testimonials indicate that it enhances immune responses and increases the body's resistance to invasion of pathogenic microbes (among the properties: resistance to fungi and bacteria, as well as viruses). These reviews are confirmed by laboratory tests and analyzes.

Parents often use a medicine to prevent the development of various diseases in children during seasonal winter-spring periods. Conducting a conservative course of prophylaxis in a child leads to the development of resistance of his body with respect to standard respiratory pathologies, and in addition to increasing the capacity for work in school.

Adults often use the drug to correct the immune system during the treatment of urethral pathologies. Using Imunoriksa during the elimination of sexually transmitted diseases reduces the curative rate several times. This indicates the high effectiveness of the drug.

Shelf life

Imunoriks is allowed to be used during the 3 years since the release of the drug.